Our Core Imaging division develops and supplies diagnostic radiopharmaceuticals and contrast media for SPECT, PET, Ultrasound, MR, X-ray, and CT imaging modalities. We provide tracers such as DaTscan™, a SPECT tracer indicated for Parkinson’s disease diagnosis and Vizamyl™, a PET tracer for Alzheimer’s disease diagnosis. In addition, we have a number of imaging agents in development.

We are seeking:

Agents that enhance the diagnostic imaging capability of X-ray, CT, MRI, SPECT, and ultrasound imaging modalities.
Late stage imaging agents in neurodegeneration, oncology, and cardiology therapy areas.
Validated imaging biomarkers to support tracer development.
Technologies associated with the use of radiopharmaceuticals and contrast media.

In-Licensing

Diagnostic Imaging